Dana Schlegel
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dana Schlegel.
Ophthalmic Genetics | 2018
Maria Fernanda Abalem; Cynthia X. Qian; Kari Branham; Dana Schlegel; Abigail T. Fahim; Naheed W. Khan; John R. Heckenlively; K. Thiran Jayasundera
ABSTRACT We report an unusual phenotype in a child with a clinical diagnosis of recessive Stargardt disease (STGD1) and two pathogenic variants in the ABCA4 gene. Typically, the diagnosis of early-onset STGD1 is challenging because children may present with a variety of fundus changes and a variable rate of progression. At the time of his initial visit, the 6-year-old boy presented with 20/200 OD (right eye) and 20/150 OS (left eye), symmetrical mild foveal atrophy without flecks on fundus exam, and foveal hypoautofluorescence surrounded by a homogeneous hyperautofluorescent background on wide-field fundus autofluorescence. Over 4 years of follow-up, the retinal atrophy continued to progress, resulting in two well-defined and concentric hyperautofluorescent rings: one ring located at the posterior pole and the other located around the peripapillary region. Visual acuity also deteriorated to counting fingers at 4ft OD and 20/500 OS. To the best of our knowledge, this phenotype has not been previously described with the ABCA4 gene.
Ophthalmic Genetics | 2018
Vaidehi S. Dedania; Jerry Y. Liu; Dana Schlegel; Chris Andrews; Kari Branham; Naheed W. Khan; David C. Musch; John R. Heckenlively; K. Thiran Jayasundera
ABSTRACT Purpose: Kinetic visual field testing is used to monitor disease course in retinal dystrophy clinical care and treatment response in treatment trials, which are increasingly recruiting children. This study investigates Goldmann visual field (GVF) changes in young children with mutation-proven retinal dystrophies as they age and with progression of the retinal degeneration. Methods: Retrospective review of children ≤ 17 years old with a mutation-proven retinal dystrophy. Objective clinical disease activity was assessed by a retinal degeneration specialist masked to GVF results. Digital quantification of GVF area was performed. Results: Twenty-nine children (58 eyes), ages 5–16, were identified. GVF area increased with age despite progression in 20 children and clinical stability in nine children. Mean ± standard error increase in GVF area/year was 333 ± 130 mm2 (I4e, p = 0.012), 720 ± 155 mm2 (III4e, p < 0.001), and 759 ± 167 mm2 (IV4e, p < 0.001), with greater increases at earlier ages. Repeatability coefficients were 7381 mm2 (I4e), 9379 mm2 (III4e), and 10346 mm2 (IV4e), indicating a large variability. At 2.5 years after the baseline GVF the area increased ≥ 20%, the criterion for positive treatment outcome defined in recent published therapeutic trials, in 38% (I4e), 34% (III4e), and 33% (IV4e) of eyes. Conclusion: In a substantial proportion of children with mutation-proven retinal dystrophies, there is a significant increase in GVF area with age, particularly those < 12 years, despite progression or stability of disease. These findings suggest that change in GVF area in children with retinal dystrophies can be an unreliable measure of response to treatment and on which to base appropriate counseling about visual impairment.
Archive | 2018
Sarwar Zahid; Kari Branham; Dana Schlegel; Mark E. Pennesi; Michel Michaelides; John R. Heckenlively; Thiran Jayasundera
OPN1LW and OPN1MW lie side by side on the X-chromosome and encode the long-wavelength (red) and middle-wavelength (green) cone opsins, respectively. Mutations in these genes cause a wide array of X-linked conditions ranging from red-green dyschromatopsia, blue cone monochromacy (BCM), cone/cone-rod dystrophy, and high myopia.
Archive | 2018
Sarwar Zahid; Kari Branham; Dana Schlegel; Mark E. Pennesi; Michel Michaelides; John Heckenlively; Thiran Jayasundera
Describes a gene and all its possible clinical phenotypes and patient characteristics, along with retinal photos depicting each possible phenotype Written by prominent retinal dystrophy specialists from the largest dystrophy centers worldwide Contains more than 80 chapters, each of which describes the clinical and photographic manifestations of a specific gene Includes stunning clinical color photographs of the retina, autofluorescence imaging, and electrophysiologic findings and cross-sectional imaging Serves as a resource to aid genetic diagnosis in patients with retinal dystrophies by retina specialists and pediatric ophthalmologists in the United States, as well as hundreds of fellows and residents that
American Journal of Ophthalmology | 2017
Peter Y. Zhao; Maria Fernanda Abalem; Daniel Nadelman; Cynthia X. Qian; Kari Branham; Dana Schlegel; Naheed W. Khan; John R. Heckenlively; Thiran Jayasundera
PURPOSE To investigate the prevalence of peripheral pigmented retinal lesions and associated clinical findings in patients with Stargardt disease. DESIGN Retrospective case series. METHODS Records at a single academic institution were reviewed for patients with genetically confirmed Stargardt disease with peripheral pigmented retinal lesions on wide-field retinal imaging. For this cohort we described demographics, clinical features, and pathogenic variants. RESULTS Out of 62 patients with Stargardt disease and wide-field retinal imaging, 14 had peripheral pigmented retinal lesions. These flat, subretinal lesions were located in the mid or far periphery and had well-defined borders, resembling congenital hypertrophy of retinal pigment epithelium (CHRPE) lesions. For this group of 14 patients, median age at initial diagnosis of Stargardt disease was 9.5 years, and the median duration of disease was 21.5 years. Median Snellen visual acuity was 20/200, and median central scotoma size was 20.0 degrees. All 14 patients had electroretinographic abnormalities. Four out of 14 patients developed new lesions during clinical follow-up. CONCLUSIONS Wide-field retinal imaging revealed the presence of peripheral pigmented retinal lesions resembling CHRPE lesions in a subset of patients with genetically confirmed Stargardt disease. Presence of these lesions may be associated with severe phenotypes of the disease.
Investigative Ophthalmology & Visual Science | 2017
Dana Schlegel; Edmond Cunningham; Xinghai Zhang; Yaman Abdulhak; Andrew DeOrio; Thiran Jayasundera
American Journal of Ophthalmology | 2017
Maria Fernanda Abalem; Benjamin Otte; Chris Andrews; Katherine A. Joltikov; Kari Branham; Abigail T. Fahim; Dana Schlegel; Cynthia X. Qian; John R. Heckenlively; Thiran Jayasundera
Investigative Ophthalmology & Visual Science | 2016
Dana Schlegel; Benjamin Katz; Vittorio Bichucher; Richmond Starbuck; Wei Xu; Jacob Durrah; Eman Al-Sharif; Andrew DeOrio; Naheed W. Khan; Kanishka Thiran Jayasundera
Investigative Ophthalmology & Visual Science | 2016
Kari Branham; Naheed W. Khan; Dana Schlegel; Kanishka Thiran Jayasundera; John R. Heckenlively
Investigative Ophthalmology & Visual Science | 2016
Vaidehi S. Dedania; Jerry Yi Liu; Dana Schlegel; Chris Andrews; Kari Branham; Naheed W. Khan; John R. Heckenlively; Kanishka Thiran Jayasundera